Yunovias pipeline includes several candidates, such as ID110521156, an oral synthetic new drug for diabetes and obesity, ID120040002, a peptic ulcer treatment in the potassium-competitive gastric acid secretion inhibitor (P-CAB) series, ID119040338, a Parkinson's disease treatment targeting adenosine A1 and A2A receptors, and ID119031166, a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
All injections are administered by a skilled and trained member of our clinical team
Weight loss prior to surgery can lower that risk, but up to now nothing's been able to help patients lose enough weight to make a difference, researchers say
The 2.5 mg solution looks the same as the 15 mg solution inside the pen
Article 9 mins Supply Chain or Distribution Failure: Navigating the New Normal Supply chain failure ranks seventh globally in 2025 and is projected to fall to twelfth place by 2028
A recent clinical study performed by the manufacturer showed that Fleet Stimulant Oral Laxative and Fleet Liquid Glycerin Suppositories produced a bowel movement after a single dose in 55.9% to 57.1% of GLP-1 patients, and after two doses in 94.1% to 94.3% of GLP-1 patients [21]
